Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease

Neurobiology of Aging

Volumn 32, Issue 11, 2011, Pages 1964-1976

  Luchetti, Sabina ^a,b   Bossers, Koen ^a   Van de Bilt, Saskia ^a   Agrapart, Vincent ^c   Morales, Rafael Ramirez ^c   Frajese, Giovanni Vanni ^c,d   Swaab, Dick F ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

Author keywords

Alzheimer's disease; Aromatase; GABA A receptors; Gene expression; Neurosteroids; Postmortem; Prefrontal cortex

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ALDO KETO REDUCTASE 1C2; AROMATASE; DIAZEPAM BINDING INHIBITOR; ESTROGEN; MESSENGER RNA; NEUROSTEROID; OXIDOREDUCTASE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 1; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BIOSYNTHESIS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GABAERGIC TRANSMISSION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEROIDOGENESIS; SYNAPSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DIAZEPAM BINDING INHIBITOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PREFRONTAL CORTEX; RECEPTORS, GABA-A; RNA, MESSENGER;

EID: 80052630059     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.12.014     Document Type: Article

References (85)

1. Bancher C., Jellinger K., Lassmann H., Fischer P., Leblhuber F. Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia. Eur. Arch. Psychiatry Clin. Neurosci. 1996, 246(3):137-146.
2. Barbaccia M.L., Costa E., Ferrero P., Guidotti A., Roy A., Sunderland T., Pickar D., Paul S.M., Goodwin F.K. Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease. Arch. Gen. Psychiatry 1986, 43(12):1143-1147.
3. Baulieu E.E. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology 1998, 23(8):963-987.
4. Behl C. Oestrogen as a neuroprotective hormone. Nat. Rev. Neurosci. 2002, 3(6):433-442.
5. Belelli D., Lambert J.J. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci. 2005, 6(7):565-575.
6. Belelli D., Casula A., Ling A., Lambert J.J. The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors. Neuropharmacology 2002, 43(4):651-661.
7. Bialek M., Zaremba P., Borowicz K.K., Czuczwar S.J. Neuroprotective role of testosterone in the nervous system. Pol. J. Pharmacol. 2004, 56(5):509-518.
8. Biggio G., Follesa P., Sanna E., Purdy R.H., Concas A. GABAA-receptor plasticity during long-term exposure to and withdrawal from progesterone. Int. Rev. Neurobiol. 2001, (46):207-241.
9. Biggio F., Gorini G., Caria S., Murru L., Mostallino M.C., Sanna E., Follesa P. Plastic neuronal changes in GABA(A) receptor gene expression induced by progesterone metabolites: in vitro molecular and functional studies. Pharmacol. Biochem. Behav. 2006, 84(4):545-554.
10. Birzniece V., Backstrom T., Johansson I.M., Lindblad C., Lundgren P., Lofgren M., Olsson T., Ragagnin G., Taube M., Turkmen S., Wahlstrom G., Wang M.D., Wihlback A.C., Zhu D. Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems. Brain Res. Rev. 2006, 51(2):212-239.
11. Bossers K., Meerhoff G., Balesar R., van Dongen J.W., Kruse C.G., Swaab D.F., Verhaagen J. Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death. Brain Pathol. 2009, 19(1):91-107.
12. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82(4):239-259.
13. Busche M.A., Eichhoff G., Adelsberger H., Abramowski D., Wiederhold K.H., Haass C., Staufenbiel M., Konnerth A., Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 2008, 321(5896):1686-1689.
14. Carroll J.C., Rosario E.R., Chang L., Stanczyk F.Z., Oddo S., LaFerla F.M., Pike C.J. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J. Neurosci. 2007, 27(48):13357-13365.
15. Cherrier M.M., Matsumoto A.M., Amory J.K., Asthana S., Bremner W., Peskind E.R., Raskind M.A., Craft S. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 2005, 64(12):2063-2068.
16. Cholerton B., Gleason C.E., Baker L.D., Asthana S. Estrogen and Alzheimer's disease: the story so far. Drugs Aging 2002, 19(6):405-427.
17. Ciriza I., Azcoitia I., Garcia-Segura L.M. Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity in vivo. J. Neuroendocrinol. 2004, 16(1):58-63.
18. Concas A., Follesa P., Barbaccia M.L., Purdy R.H., Biggio G. Physiological modulation of GABA(A) receptor plasticity by progesterone metabolites. Eur. J. Pharmacol. 1999, 375(1-3):225-235.
19. Costa E., Cheney D.L., Grayson D.R., Korneyev A., Longone P., Pani L., Romeo E., Zivkovich E., Guidotti A. Pharmacology of neurosteroid biosynthesis. Role of the mitochondrial DBI receptor (MDR) complex. Ann. N. Y. Acad. Sci. 1994, 746:223-242.
20. Djebaili M., Guo Q., Pettus E.H., Hoffman S.W., Stein D.G. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J. Neurotrauma 2005, 22(1):106-118.
21. Do Rego J.L., Seong J.Y., Burel D., Leprince J., Luu-The V., Tsutsui K., Tonon M.C., Pelletier G., Vaudry H. Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. Front Neuroendocrinol. 2009.
22. Dubrovsky B.O. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29(2):169-192.
23. Farrant M., Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci. 2005, 6(3):215-229.
24. Ferrarese C., Appollonio I., Frigo M., Meregalli S., Piolti R., Tamma F., Frattola L. Cerebrospinal fluid levels of diazepam-binding inhibitor in neurodegenerative disorders with dementia. Neurology 1990, 40(4):632-635.
25. Ferrero P., Benna P., Costa P., Tarenzi L., Baggio G., Bergamasco B., Bergamini L. Diazepam binding inhibitor-like immunoreactivity (DBI-LI) in human CSF. Correlations with neurological disorders. J. Neurol. Sci. 1988, 87(2-3):327-349.
26. Follesa P., Mostallino M.C., Biggio F., Gorini G., Caria S., Busonero F., Murru L., Mura M.L., Sanna E., Biggio G. Distinct patterns of expression and regulation of GABA receptors containing the delta subunit in cerebellar granule and hippocampal neurons. J. Neurochem. 2005, 94(3):659-671.
27. Francis P.T. Glutamatergic systems in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2003, 18(Suppl. 1):S15-S21.
28. Garay L., Deniselle M.C., Lima A., Roig P., De Nicola A.F. Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis. J. Steroid Biochem. Mol. Biol. 2007, 107(3-5):228-237.
29. Garcia-Ovejero D., Azcoitia I., DonCarlos L.L., Melcangi R.C., Garcia-Segura L.M. Glia-neuron crosstalk in the neuroprotective mechanisms of sex steroid hormones. Brain Res. Brain Res. Rev. 2005, 48(2):273-286.
30. Garcia-Segura L.M. Aromatase in the brain: not just for reproduction anymore. J. Neuroendocrinol. 2008, 20(6):705-712.
31. Genazzani A.R., Pluchino N., Luisi S., Luisi M. Estrogen, cognition and female ageing. Hum. Reprod. Update 2007, 13(2):175-187.
32. Gonzalez Deniselle M.C., Garay L., Gonzalez S., Saravia F., Labombarda F., Guennoun R., Schumacher M., De Nicola A.F. Progesterone modulates brain-derived neurotrophic factor and choline acetyltransferase in degenerating Wobbler motoneurons. Exp. Neurol. 2007, 203(2):406-414.
33. Gouras G.K., Xu H., Gross R.S., Greenfield J.P., Hai B., Wang R., Greengard P. Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. Proc. Natl. Acad. Sci. U.S.A. 2000, 97(3):1202-1205.
34. He J., Hoffman S.W., Stein D.G. Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. Restor. Neurol. Neurosci. 2004, 22(1):19-31.
35. He X.Y., Wegiel J., Yang Y.Z., Pullarkat R., Schulz H., Yang S.Y. Type 10 17beta-hydroxysteroid dehydrogenase catalyzing the oxidation of steroid modulators of gamma-aminobutyric acid type A receptors. Mol. Cell Endocrinol. 2005, 229(1-2):111-117.
36. Herd M.B., Belelli D., Lambert J.J. Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacol. Ther. 2007, 116(1):20-34.
37. Hogervorst E. Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men. Evid. Based Med. 2008, 13(3):71.
38. Kask K., Backstrom T., Nilsson L.G., Sundstrom-Poromaa I. Allopregnanolone impairs episodic memory in healthy women. Psychopharmacology (Berl) 2008, 199(2):161-168.
39. Labombarda F., Gonzalez S., Gonzalez Deniselle M.C., Garay L., Guennoun R., Schumacher M., De Nicola A.F. Progesterone increases the expression of myelin basic protein and the number of cells showing NG2 immunostaining in the lesioned spinal cord. J. Neurotrauma 2006, 23(2):181-192.
40. Lanctot K.L., Herrmann N., Rothenburg L., Eryavec G. Behavioral correlates of GABAergic disruption in Alzheimer's disease. Int. Psychogeriatr. 2007, 19(1):151-158.
41. Leichtnam M.L., Rolland H., Wuthrich P., Guy R.H. Testosterone hormone replacement therapy: state-of-the-art and emerging technologies. Pharm. Res. 2006, 23(6):1117-1132.
42. Lethaby A., Hogervorst E., Richards M., Yesufu A., Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst. Rev. 2008, (1):CD003122.
43. Li R., Shen Y., Yang L.B., Lue L.F., Finch C., Rogers J. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex. J. Neurochem. 2000, 75(4):1447-1454.
44. Lin H.K., Steckelbroeck S., Fung K.M., Jones A.N., Penning T.M. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 2004, 69(13-14):795-801.
45. Liu X.A., Zhu L.Q., Zhang Q., Shi H.R., Wang S.H., Wang Q., Wang J.Z. Estradiol attenuates tau hyperphosphorylation induced by upregulation of protein kinase-A. Neurochem. Res. 2008, 33(9):1811-1820.
46. Lowe S.L., Francis P.T., Procter A.W., Palmer A.M., Davison A.N., Bowen D.M. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain 1988, 111(Pt 4):785-799.
47. Lu P.H., Masterman D.A., Mulnard R., Cotman C., Miller B., Yaffe K., Reback E., Porter V., Swerdloff R., Cummings J.L. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch. Neurol. 2006, 63(2):177-185.
48. Manly J.J., Merchant C.A., Jacobs D.M., Small S.A., Bell K., Ferin M., Mayeux R. Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 2000, 54(4):833-837.
49. Marx C.E., Trost W.T., Shampine L.J., Stevens R.D., Hulette C.M., Steffens D.C., Ervin J.F., Butterfield M.I., Blazer D.G., Massing M.W., Lieberman J.A. The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol. Psychiatry 2006, 60(12):1287-1294.
50. Melcangi R.C., Garcia-Segura L.M., Mensah-Nyagan A.G. Neuroactive steroids: state of the art and new perspectives. Cell Mol. Life Sci. 2008, 65(5):777-797.
51. Mellon S.H., Vaudry H. Biosynthesis of neurosteroids and regulation of their synthesis. Int. Rev. Neurobiol. 2001, (46):33-78.
52. Mohler H. GABA(A) receptor diversity and pharmacology. Cell Tissue Res. 2006, 326(2):505-516.
53. Mountjoy C.Q. Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia. Brain 1984, 107(2):507-518.
54. Mulnard R.A. Methodological issues in estrogen treatment trials for Alzheimer's disease. Ann. N. Y. Acad. Sci. 2005, 1052:173-181.
55. Nilsen J., Brinton R.D. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(18):10506-10511.
56. Papadopoulos V., Amri H., Boujrad N., Cascio C., Culty M., Garnier M., Hardwick M., Li H., Vidic B., Brown A.S., Reversa J.L., Bernassau J.M., Drieu K. Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids 1997, 62(1):21-28.
57. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapere J.J., Lindemann P., Norenberg M.D., Nutt D., Weizman A., Zhang M.R., Gavish M. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 2006, 27(8):402-409.
58. Penning T.M., Jin Y., Heredia V.V., Lewis M. Structure-function relationships in 3alpha-hydroxysteroid dehydrogenases: a comparison of the rat and human isoforms. J. Steroid Biochem. Mol. Biol. 2003, 85(2-5):247-255.
59. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29(9):e45.
60. Pike C.J., Rosario E.R., Nguyen T.V. Androgens, aging, and Alzheimer's disease. Endocrine 2006, 29(2):233-241.
61. Pluchino N., Luisi M., Lenzi E., Centofanti M., Begliuomini S., Freschi L., Ninni F., Genazzani A.R. Progesterone and progestins: effects on brain, allopregnanolone and beta-endorphin. J. Steroid Biochem. Mol. Biol. 2006, 102(1-5):205-213.
62. Reinikainen K.J., Paljarvi L., Huuskonen M., Soininen H., Laakso M., Riekkinen P.J. A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J. Neurol. Sci. 1988, 84(1):101-116.
63. Rosario E.R., Chang L., Stanczyk F.Z., Pike C.J. Age-related testosterone depletion and the development of Alzheimer disease. JAMA 2004, 292(12):1431-1432.
64. Rosario E.R., Carroll J.C., Oddo S., LaFerla F.M., Pike C.J. Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J. Neurosci. 2006, 26(51):13384-13389.
65. Rosario E.R., Chang L., Head E.H., Stanczyk F.Z., Pike C.J. Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease. Neurobiol. Aging 2009.
66. Rossor M.N., Garrett N.J., Johnson A.L., Mountjoy C.Q., Roth M., Iversen L.L. A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain 1982, 105(Pt 2):313-330.
67. Sayeed I., Guo Q., Hoffman S.W., Stein D.G. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann. Emerg. Med. 2006, 47(4):381-389.
68. Sayeed I., Wali B., Stein D.G. Progesterone inhibits ischemic brain injury in a rat model of permanent middle cerebral artery occlusion. Restor. Neurol. Neurosci. 2007, 25(2):151-159.
69. Schumacher M., Akwa Y., Guennoun R., Robert F., Labombarda F., Desarnaud F., Robel P., De Nicola A.F., Baulieu E.E. Steroid synthesis and metabolism in the nervous system: trophic and protective effects. J. Neurocytol. 2000, 29(5-6):307-326.
70. Schumacher M., Weill-Engerer S., Liere P., Robert F., Franklin R.J., Garcia-Segura L.M., Lambert J.J., Mayo W., Melcangi R.C., Parducz A., Suter U., Carelli C., Baulieu E.E., Akwa Y. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog. Neurobiol. 2003, 71(1):3-29.
71. Schumacher M., Guennoun R., Stein D.G., De Nicola A.F. Progesterone: therapeutic opportunities for neuroprotection and myelin repair. Pharmacol. Ther. 2007, 116(1):77-106.
72. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289(20):2651-2662.
73. Stein D.G., Wright D.W., Kellermann A.L. Does progesterone have neuroprotective properties?. Ann. Emerg. Med. 2008, 51(2):164-172.
74. Stell B.M., Brickley S.G., Tang C.Y., Farrant M., Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(24):14439-14444.
75. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur. J. Endocrinol. 2001, 145(6):669-679.
76. Thigpen A.E., Silver R.I., Guileyardo J.M., Casey M.L., McConnell J.D., Russell D.W. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J. Clin. Invest. 1993, 92(2):903-910.
77. Thomas A.J., Nockels R.P., Pan H.Q., Shaffrey C.I., Chopp M. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine (Phila Pa 1976) 1999, 24(20):2134-2138.
78. van Wingen G., van Broekhoven F., Verkes R.J., Petersson K.M., Backstrom T., Buitelaar J., Fernandez G. How progesterone impairs memory for biologically salient stimuli in healthy young women. J. Neurosci. 2007, 27(42):11416-11423.
79. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van R.N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3(7). RESEARCH0034.
80. Vongher J.M., Frye C.A. Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration. Pharmacol. Biochem. Behav. 1999, 64(4):777-785.
81. Wang J.M., Irwin R.W., Liu L., Chen S., Brinton R.D. Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent. Curr. Alzheimer Res. 2007, 4(5):510-517.
82. Weill-Engerer S., David J.P., Sazdovitch V., Liere P., Eychenne B., Pianos A., Schumacher M., Delacourte A., Baulieu E.E., Akwa Y. Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J. Clin. Endocrinol. Metab. 2002, 87(11):5138-5143.
83. Wright D.W., Kellermann A.L., Hertzberg V.S., Clark P.L., Frankel M., Goldstein F.C., Salomone J.P., Dent L.L., Harris O.A., Ander D.S., Lowery D.W., Patel M.M., Denson D.D., Gordon A.B., Wald M.M., Gupta S., Hoffman S.W., Stein D.G. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann. Emerg. Med. 2007, 49(4):391-402.
84. Xiao G., Wei J., Yan W., Wang W., Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit. Care 2008, 12(2):R61.
85. Yague J.G., Munoz A., de Monasterio-Schrader P., Defelipe J., Garcia-Segura L.M., Azcoitia I. Aromatase expression in the human temporal cortex. Neuroscience 2006, 138(2):389-401.